Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis

Rheumatology

Volumn 47, Issue 6, 2008, Pages 932-933

  Jung, N ^a   Owczarczyk, K ^a   Hellmann, M ^a   Lehmann, C ^a   Fatkenheuer G ^a   Hallek, M ^a   Rubbert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANALGESIC AGENT; AZATHIOPRINE; CHLOROQUINE; GOLD COMPLEX; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TUBERCULOSTATIC AGENT; VORICONAZOLE;

ADULT; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; KIDNEY DYSFUNCTION; LETTER; LOBECTOMY; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG TUBERCULOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASPERGILLOSIS; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TUBERCULOSIS, PULMONARY;

EID: 44849121954     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken143     Document Type: Letter

References (10)

1. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: A 20 year followup study. J Rheumatol 2003;30:958-65.
2. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007;46:1157-60.
3. Curtis JR, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
4. Smolen JS, Keystone EC, Emery P et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.
5. Cornillet A, Camus C, Nimubona S et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin Infect Dis 2006;43:577-84.
6. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
7. van der Velden WJ, Blijlevens NM, Klont RR, Donnelly JP, Verweij PE. Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol 2006;85:621-3.
8. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: The remission, the relapse, and the complication. Transplantation 2002;73:100-4.
9. Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 2007;86:225-6.
10. Montagnoli C, Bozza S, Bacci A et al. A role for antibodies in the generation of memory antifungal immunity. Eur J Immunol 2003;33:1193-204.